Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance

Siegel, 2016, Cancer statistics, 2016, CA Cancer J Clin, 66, 7, 10.3322/caac.21332

Ibrahim, 2017, Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer, Fam Cancer, 16, 111, 10.1007/s10689-016-9915-3

Canto, 2013, International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer, Gut, 62, 339, 10.1136/gutjnl-2012-303108

Klein, 2004, Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds, Cancer Res, 64, 2634, 10.1158/0008-5472.CAN-03-3823

Klein, 2002, Evidence for a major gene influencing risk of pancreatic cancer, Genet Epidemiol, 23, 133, 10.1002/gepi.1102

Jones, 2009, Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene, Science, 324, 217, 10.1126/science.1171202

van Lier, 2010, High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations, Am J Gastroenterol, 105, 1258, 10.1038/ajg.2009.725

Zhen, 2015, BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study, Genet Med, 17, 569, 10.1038/gim.2014.153

Rebours, 2008, Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series, Am J Gastroenterol, 103, 111, 10.1111/j.1572-0241.2007.01597.x

Al-Sukhni, 2008, Germline BRCA1 mutations predispose to pancreatic adenocarcinoma, Hum Genet, 124, 271, 10.1007/s00439-008-0554-0

Kastrinos, 2009, Risk of pancreatic cancer in families with Lynch syndrome, JAMA, 302, 1790, 10.1001/jama.2009.1529

Roberts, 2012, ATM mutations in patients with hereditary pancreatic cancer, Cancer Discov, 2, 41, 10.1158/2159-8290.CD-11-0194

Al-Sukhni, 2012, Screening for pancreatic cancer in a high-risk cohort: an eight-year experience, J Gastrointest Surg, 16, 771, 10.1007/s11605-011-1781-6

Bartsch, 2013, Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?, Fam Cancer, 12, 89, 10.1007/s10689-012-9582-y

Canto, 2006, Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study, Clin Gastroenterol Hepatol, 4, 766, 10.1016/j.cgh.2006.02.005

Canto, 2004, Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach, Clin Gastroenterol Hepatol, 2, 606, 10.1016/S1542-3565(04)00244-7

Canto, 2012, Frequent detection of pancreatic lesions in asymptomatic high-risk individuals, Gastroenterology, 142, 796, 10.1053/j.gastro.2012.01.005

Kimmey, 2002, Screening and surveillance for hereditary pancreatic cancer, Gastrointest Endosc, 56, S82, 10.1016/S0016-5107(02)70092-8

Langer, 2009, Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer, Gut, 58, 1410, 10.1136/gut.2008.171611

Ludwig, 2011, Feasibility and yield of screening in relatives from familial pancreatic cancer families, Am J Gastroenterol, 106, 946, 10.1038/ajg.2011.65

Schneider, 2011, German national case collection for familial pancreatic cancer (FaPaCa): ten years experience, Fam Cancer, 10, 323, 10.1007/s10689-010-9414-x

Vasen, 2010, Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation, Gastroenterology, 140, 850, 10.1053/j.gastro.2010.11.048

Poley, 2009, The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer, Am J Gastroenterol, 104, 2175, 10.1038/ajg.2009.276

Vasen, 2016, Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers, J Clin Oncol, 34, 2010, 10.1200/JCO.2015.64.0730

Harinck, 2016, A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals, Gut, 65, 1505, 10.1136/gutjnl-2014-308008

Tanaka, 2006, International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas, Pancreatology, 6, 17, 10.1159/000090023

Tanaka, 2012, International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas, Pancreatology, 12, 183, 10.1016/j.pan.2012.04.004

Kang, 2011, Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms, Clin Gastroenterol Hepatol, 9, 87, 10.1016/j.cgh.2010.09.008

Kwong, 2015, Rapid growth rates of suspected pancreatic cyst branch duct intraductal papillary mucinous neoplasms predict malignancy, Dig Dis Sci, 60, 2800, 10.1007/s10620-015-3679-8

Vege, 2015, American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts, Gastroenterology, 148, 819, 10.1053/j.gastro.2015.01.015

2010

2017

Catalano, 2009, EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification, Gastrointest Endosc, 69, 1251, 10.1016/j.gie.2008.07.043

Maguchi, 2011, Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan, Pancreas, 40, 364, 10.1097/MPA.0b013e31820a5975

Tada, 2006, Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients, Clin Gastroenterol Hepatol, 4, 1265, 10.1016/j.cgh.2006.07.013

Hisada, 2017, Natural history of intraductal papillary mucinous neoplasm and non-neoplastic cyst: long-term imaging follow-up study, J Hepatobiliary Pancreat Sci, 12, 645

Kamata, 2014, Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms, Endoscopy, 46, 22

Eshleman, 2015, KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound, Clin Gastroenterol Hepatol, 13, 963, 10.1016/j.cgh.2014.11.028

Kanda, 2013, Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts, Gut, 62, 1024, 10.1136/gutjnl-2012-302823

Kanda, 2013, Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia, Clin Gastroenterol Hepatol, 11, 719, 10.1016/j.cgh.2012.11.016

Yu, 2017, Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms, Gut, 66, 1677, 10.1136/gutjnl-2015-311166

Cohen, 2017, Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers, Proc Natl Acad Sci U S A, 114, 10202, 10.1073/pnas.1704961114

Suenega M, Yu J, Shindo K, et al. Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance [published online ahead of print May 25, 2018]. Clin Cancer Res https://doi.org/10.1158/1078-0432.CCR-17-2463.